M. Heep - Concepedia

Author

M. Heep

Basilea Pharmaceutica (Switzerland)

Also Known As

M Heep, M. Heep, Markus Heep

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Basilea Pharmaceutica (Switzerland)Institute of Medical Microbiology and Hygiene University of Regensburg Novartis (Switzerland)University Hospital Regensburg

About

M. Heep is an author at Basilea Pharmaceutica (Switzerland) specializing in medicine, antimicrobial resistance, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1K
2	Health Sciences	7	7	900
3	Microbiology	5	5	613
4	Gastroenterology	1	1	99
5	Hepatology	1	1	67

M. Heep

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Frequency of <i>rpoB</i> Mutations Inside and Outside the Cluster I Region in Rifampin-Resistant Clinical <i>Mycobacterium tuberculosis</i> Isolates M. Heep, Barbara Brandstätter, Ulrich M. Rieger, Journal of Clinical Microbiology Pulmonary TuberculosisAntimicrobial Resistance GeneRpob GeneHealth SciencesGenetics	2001	228
Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria Gary J. Noel, Karen Amsler, M. Heep, Antimicrobial Agents and Chemotherapy Antimicrobial SusceptibilityHealth SciencesAntibioticsVancomycin 1Complicated Skin	2007	188
Rifampin and Rifabutin Resistance Mechanism in <i>Helicobacter pylori</i> M. Heep, Daniela Beck, E. Bayerdörffer, Antimicrobial Agents and Chemotherapy Medical MicrobiologyAntimicrobial Resistance GeneRpob GeneHealth SciencesRifabutin Resistance Mechanism	1999	176
Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers Anne Schmitt‐Hoffmann, Brigitte Roos, M. Heep, Antimicrobial Agents and Chemotherapy	2005	169
Mutations in the Beginning of the <i>rpoB</i> Gene Can Induce Resistance to Rifamycins in both <i>Helicobacter pylori</i> and <i>Mycobacterium tuberculosis</i> M. Heep, Ulrich M. Rieger, Daniela Beck, Antimicrobial Agents and Chemotherapy	2000	148
Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers Anne Schmitt‐Hoffmann, Brigitte Roos, J. Maares, Antimicrobial Agents and Chemotherapy	2005	139
Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy M. Heep, Manfred Kist, Sonja Strobel, European Journal of Clinical Microbiology & Infectious Diseases Antimicrobial Resistance GeneAntimicrobial SusceptibilityHealth SciencesMicrobiologyAntibiotic Resistance	2000	122
Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment H. Böck, H. Koop, Norbert Lehn, Journal of Clinical Gastroenterology Hp EradicationEradication TherapyAntimicrobial StewardshipHealth SciencesMedicine	2000	99
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus Peter Warn, Juan Alejandro Neira Mosquera, Jochen Spickermann, Journal of Antimicrobial Chemotherapy	2006	77
Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557 Anne Schmitt‐Hoffmann, Brigitte Roos, Jochen Spickermann, Antimicrobial Agents and Chemotherapy Healthy SubjectsPathologyPharmacotherapyAntimicrobial ChemotherapyModerate Liver Impairment	2009	67

Page 1